Immunotherapy Treatment for Triple Negative Breast Cancer

• Main Authors: Elizabeth R. Berger (Author), Tristen Park (Author), Angeleke Saridakis (Author), Mehra Golshan (Author), Rachel A. Greenup (Author), Nita Ahuja (Author)
• Formato: Livro
• Publicado em: MDPI AG, 2021-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival...